TransMedics Group (NASDAQ:TMDX) Price Target Raised to $125.00

TransMedics Group (NASDAQ:TMDX) had its price objective upped by analysts at Oppenheimer from $105.00 to $125.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 32.80% from the company’s current price.

A number of other equities analysts have also recently weighed in on the stock. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler assumed coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price objective for the company. Finally, Morgan Stanley increased their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $106.00.

TransMedics Group Stock Down 3.2 %

TMDX stock opened at $94.13 on Wednesday. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The company has a market capitalization of $3.08 billion, a P/E ratio of -122.25 and a beta of 1.99. The firm’s fifty day simple moving average is $83.23 and its 200-day simple moving average is $75.63. TransMedics Group has a 12 month low of $36.42 and a 12 month high of $99.63.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same quarter in the prior year, the firm earned ($0.08) EPS. The company’s revenue for the quarter was up 132.9% on a year-over-year basis. As a group, equities research analysts forecast that TransMedics Group will post -0.14 earnings per share for the current year.

Insider Buying and Selling

In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $85.45, for a total transaction of $1,281,750.00. Following the completion of the sale, the chief financial officer now directly owns 13,075 shares in the company, valued at $1,117,258.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Tamer I. Khayal sold 4,947 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $80.36, for a total value of $397,540.92. Following the sale, the insider now owns 25,185 shares of the company’s stock, valued at approximately $2,023,866.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $85.45, for a total transaction of $1,281,750.00. Following the completion of the transaction, the chief financial officer now owns 13,075 shares of the company’s stock, valued at approximately $1,117,258.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 117,078 shares of company stock valued at $9,972,971. Insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in TMDX. Venturi Wealth Management LLC purchased a new stake in shares of TransMedics Group in the first quarter worth approximately $30,000. Cutler Group LLC CA raised its position in TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after acquiring an additional 600 shares in the last quarter. RiverPark Advisors LLC bought a new position in TransMedics Group during the third quarter valued at approximately $60,000. First Horizon Advisors Inc. raised its position in TransMedics Group by 26.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after acquiring an additional 222 shares in the last quarter. Finally, Van ECK Associates Corp raised its position in TransMedics Group by 39.0% during the third quarter. Van ECK Associates Corp now owns 2,127 shares of the company’s stock valued at $116,000 after acquiring an additional 597 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.